A prediction for 2025 by Michael Meucci, president and CEO of Arcadia.
As we enter 2025, the healthcare industry is poised for a leap forward in the sophistication of value-based care (VBC) strategies. With CMS aiming to have all Medicare beneficiaries in value-based arrangements by 2030, the push is intensifying. In the coming year, I expect to see new entrants exploring risk-based contracts while existing players take on higher levels of risk. I also expect existing players to shift toward more mature and strategic approaches to VBC.
Meucci
While coding accuracy, quality documentation and gap closures are essential, they are no longer enough to drive differentiation or success in the increasingly competitive landscape. Practices and ACOs [accountable care organizations] that thrive in 2025 will move beyond these basic levers, tapping into strategies that foster integration and innovation across all levels. This means strategically bringing specialists into VBC arrangements to provide a holistic approach to patient care and aligning incentives across the broader care team.
Moreover, I anticipate a greater focus on understanding performance benchmarks, both at the practice and market levels. Leading VBC organizations will leverage advanced data insights to improve decision-making, assessing local and regional competitive benchmarks to refine who to add to an ACO and to set strategic performance targets for ACO members. This data-driven clarity will shine a brighter light on individual provider performance and push the industry toward more collaborative accountable care models.
The Global Impact of Underfunding Women’s Health
February 20th 2025Bias and stigma are to blame for the way women’s health research has fallen behind, according to Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's Integrated Health and Valentina Sartori, Ph.D., the leader of the McKinsey Health Institute's Life Sciences Practice in Europe.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Solid Biosciences Reports Positive Data from DMD Gene Therapy Trial
February 19th 2025Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively to muscle cells.
Read More